Photobiomodulation therapy retarded axial length growth in children with myopia: evidence from a 12-month randomized controlled trial evidence
Zhou L, Tong L, Li Y, Williams BT, Qiu K
Scientific reports · 36 citas
Cómo se estudió
- Diseño
- Ensayo controlado aleatorizado (indexado por PubMed)
- Estudiado en
- Personas
- Resultado principal
- Marcadores de salud y funcionamiento
Quién lo pagó
- Financiación
- Financiación independiente
- Universidad u hospital
- Xuzhou Medical University
- Universidad u hospital
- The grand from Xuzhou medical university affiliated Xuzhou Municipal hospital development Grands
- Gobierno
- the grant from the Science and Technology Program of Ningbo, China
Según 3 financiadores declarados y la declaración de financiación del texto completo.
Publicación
- Publicado
- 2023-02-27 · Sci Rep · vol. 13 · número 1 · pág. 3321
- Editorial
- Nature Portfolio
- Citado
- 40 citas · más que el 98% de estudios similares · 6.7× el promedio de su campo
- Impacto
- Entre el 10 % más citado de su campo
- Referencias
- 20 trabajos
- Acceso
- Acceso abierto (revista) · CC-BY
- Áreas de investigación
- Ophthalmology and Visual Impairment Studies · Ocular and Laser Science Research · Laser Applications in Dentistry and Medicine
- Palabras clave
- low-level laser therapy, myopia control, axial length growth, children, low myopia, choroidal thickness, anterior chamber depth, corneal power, cycloplegic refraction
- MeSH
- humans, myopia, mydriatics, vision tests, refraction, ocular, child, low-level light therapy
5 autores
- Lei Zhou
- Liyang Tong
- Ying Li🇨🇳Xuzhou Medical College
- Bruce T. Williams
- Kaikai Qiu · autor de correspondencia
Resumen
El texto original del estudio, en el idioma en que se publicó.
To determine whether photobiomodulation (PBM) therapy can retard ocular axial length (AL) in children with myopia. A randomized controlled clinical trial was conducted on two consecutive cohorts of 50 eligible children aged 8-12 years with ≤ - 0.75 Diopter (D) of spherical equivalent refraction (SER). Participants were randomly assigned to the intervention group (n = 25) and treated with PBM therapy or the control group (n = 25) and treated with single vision spectacles only. At the 12-month follow-up, the changes in AL and cycloplegic SER from baseline were both compared between the two groups. In addition, the subfoveal choroidal thickness (SFChT), anterior chamber depth (ACD), and central corneal refractive power (CCP) were analysed at the 3-, 6-, 9-, and 12-month follow-ups, respectively. Among the 50 children, 78% were included at the final follow-up, with a mean age of 9.7 ± 1.5 years and a mean SER of - 2.56 ± 1.70. The mean difference in AL growth between the two groups at 12 months was 0.50 mm (PBM vs. Control, - 0.02 mm ± 0.11 vs. 0.48 mm ± 0.16, P < 0.001), and the mean difference in cycloplegic SER at 12 months was + 1.25 D (PBM vs. Control, + 0.28 D ± 0.26 vs. - 0.97 D ± 0.25, P < 0.001). There were no significant differences in any of the other parameters (including SFChT, ACD, and CCP) between the two groups at any time point. PBM therapy is an effective intervention for slightly decreasing the AL to control myopia in children.Trial registration: Chinese Clinical Trial Registration Number: ChiCTR2100043619. Registered on 23/02/2021; prospectively registered. http://www.chictr.org.cn/showproj.aspx?proj=121302 .
Resumen vía Europe PMC. Los derechos de autor siguen siendo de los autores o la editorial (CC BY).
Confianza de la comunidad
Cargando…
¿Cuánto confías en los hallazgos de este estudio?
Comentarios
¿Algo está mal aquí?
Señala este estudio si su información, etiquetas o financiación parecen incorrectas. Un editor revisa cada señalamiento.
Información educativa sobre investigación publicada. No es consejo médico ni una recomendación para empezar o dejar nada.